USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Maine BioTek, Inc.
Address:
259 MAIN STREET
Suite 208
WINTERPORT, ME 04496 0408
Phone:
(207) 223-4662
URL:
N/A
EIN:
N/A
DUNS:
121149640
Number of Employees:
3
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $439,305.00 5
SBIR Phase II $1,091,393.00 3

Award List:

Preparation of an IHN Virus Whole Killed Vaccine: Retention of Neutralizing Epitope Integrity of the IHN Virus Glycoprotein During Viral...

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$75,000.00
Agency:
USDA
Principal Investigator:
Abstract:
NON-TECHNICAL SUMMARY: IHN disease in farmed salmon and trout exerts a negative impact on the productivity and profitability of the aquaculture industry. The purpose of this project is to produce an efficacious, safe and cost-effective killed IHN virus vaccine. The vaccine would decrease or… More

Recombinant ISA Virus Vaccine

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$75,000.00
Agency:
USDA
Principal Investigator:
Abstract:
NON-TECHNICAL SUMMARY: ISA virus, an unclassified Orthomyxoviridae is an emerging pathogen associated with disease in farmed Atlantic salmon. Losses incurred in Maine due to ISA alone in 2002 are estimated to be over $12 million (US). In response to the threat, salmon producers have stated that an… More

SBIR Phase I: Recombinant Infectious Hematopoietic Necrosis (IHN ) Virus G Protein Vaccine

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$94,376.00
Agency:
NSF
Principal Investigator:
Eric Anderson
Abstract:
This Small Business Innovation Research Phase I project is to develop a vaccine for the control of infectious hematopoietic necrosis (IHN) disease of salmon and trout. An efficacious, safe and reasonably priced IHN virus vaccine would improve the productivity of the finfish aquaculture industry in… More

Recombinant ISA Virus Vaccine

Award Year / Program / Phase:
2004 / SBIR / Phase II
Award Amount:
$296,000.00
Agency:
USDA
Principal Investigator:
Abstract:
Infectious salmon anemia (ISA) virus is an emerging pathogen of farmed Atlantic salmon (Salmo salar). The virus is among the fish pathogens listed in the Aquatic Animal Health Code of the Office International des Epizooties (OIE). As such, ISA is a notifiable disease and compulsory eradication… More

Potency, Efficacy and Standardization of a Whole Killed IHN Virus Vaccine

Award Year / Program / Phase:
2005 / SBIR / Phase II
Award Amount:
$296,000.00
Agency:
USDA
Principal Investigator:
Abstract:
The salmon and to a lesser extent the trout aquaculture industries in North America consider infectious hematopoietic necrosis virus a major threat to the current and future economic viability and sustainable growth of the industry. As such, development of an efficacious IHN virus vaccine has been… More

SBIR Phase I: Atlantic Cod Nodavirus Vaccine

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$99,929.00
Agency:
NSF
Principal Investigator:
Abstract:
This Small Business Innovation Research (SBIR) Phase I project will develop a novel recombinant vaccine for the control of viral nervous necrosis (VNN) of cultured Atlantic cod (Gadus morhua) in New England and Atlantic Canada. The Atlantic cod nodavirus causes VNN which is characterized by the… More

A Multivalent Bacterial Vaccine for Atlantic Cod

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$95,000.00
Agency:
DOC
Principal Investigator:
Sharon Clouthier, President
Abstract:
The goal of this project (Phase I ¿ III) is to develop a vaccine for the control of diseases in Atlantic cod caused by L. anguillarum and A. salmonicida. To accomplish this we have established the following sequential technical Phase I objectives: (1) identify bacterial growth conditions suitable… More

SBIR Phase II: Atlantic Cod Nodavirus Vaccine

Award Year / Program / Phase:
2007 / SBIR / Phase II
Award Amount:
$499,393.00
Agency:
NSF
Principal Investigator:
Abstract:
This Small Business Innovation Research (SBIR) Phase II project of develops a recombinant vaccine for the prevention of nodavirus disease of cultured Atlantic cod, fisheries of growing importanct to New England and Atlantic Canada. The recombinant technology used to build the vaccine is economical,… More